EMEA-000480-PIP01-08-M14
Key facts
| Invented name |
Brilique
|
| Active substance |
ticagrelor
|
| Therapeutic area |
|
| Decision number |
P/0175/2021
|
| PIP number |
EMEA-000480-PIP01-08-M14
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Prevention of thromboembolic events
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
AstraZeneca AB
Tel. +46 8553 27591 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|
| Compliance procedure number |
EMEA-C-000480-PIP01-08-M14
|
| Compliance opinion date |
25/06/2021
|
| Compliance outcome |
positive
|